Key results 2015

For three of the eight key variables the Finnish results were in line with the ESPAD average. This is true for lifetime use of inhalants, lifetime use of tranquillisers or sedatives without prescription and cigarette use during the last 30 days. For the five remaining variables the results were all below average. In relative terms this was especially notable for lifetime use of cannabis, illicit drugs other than cannabis and NPS. In addition the results for the two alcohol measures were comparatively low, with prevalence rates at approximately two thirds of the ESPAD average. The overall impression is that Finland, in the ESPAD context, is primarily a low-prevalence country.

Country facts:
Area: 304500 km2
Population: 5,4 million

Country contacts: 

Kirsimarja Raitasalo
Principal Investigator

National Institute for Health and Welfare (THL)
Mannerheimintie 168b (5th floor)
00271 Helsinki
Tel: +358 29 524 7005